SCHOTT PHARMA

Annual Financial Statements

for the financial year
from 1 October 2023
to 30 September 2024

Contents

COMBINED MANAGEMENT REPORT FOR THE FINANCIAL YEAR 2023/2024

The Management Report of SCHOTT Pharma AG & Co. KGaA, Mainz, and the Group Management Report are presented combined, in conformity with section 315 (5) in conjunction with section 298 (2) HGB, and published in the Annual Report of SCHOTT Pharma AG & Co. KGaA.

The Annual Financial Statements and the Management Report of SCHOTT Pharma AG & Co. KGaA (combined with the Group Management Report) for the financial year 2023/2024 are submitted to (and published in) the German Company Register (*Unternehmensregister*), the central platform for making company data publicly available.

Furthermore, the Annual Financial Statements and the Annual Report of SCHOTT Pharma AG & Co. KGaA, Mainz, for the financial year 2023/2024 are available on our website at https://ir.schott-pharma.com/investor-relations/news-publications/reports-and-presentations/.

BALANCE SHEET AS OF 30 SEPTEMBER 2024

Assets

EUR	30 Sep 2024	30 Sep 2023
A. Fixed assets		
I. Intangible fixed assets		
Purchased concessions, industrial property rights and similar rights and assets, as well as licences in such rights and assets	181,358.42	381,956.31
	181,358.42	381,956.31
II. Property, plant and equipment		
1. Land, land rights and buildings	10,524,715.53	6,207,821.19
2. Technical equipment and machinery	52,789,371.65	39,961,901.23
3. Other equipment, operating and office equipment	13,061,351.91	10,827,343.93
4. Advance payments made and assets under construction	64,187,350.83	53,102,568.43
	140,562,789.92	110,099,634.78
III. Financial assets		
1. Shares in affiliated companies	484,457,723.81	479,963,676.27
2. Loans to affiliated companies	4,000,000.00	103,510,024.95
3. Joint ventures	4,193,466.48	4,193,466.48
	492,651,190.29	587,667,167.70
	633,395,338.63	**698,148,758.79**
B. Current assets		
I. Inventories		
1. Raw materials, consumables and supplies	7,157,515.16	6,888,101.20
2. Work in progress	1,886,195.61	786,794.24
3. Finished goods and merchandise	7,508,696.08	8,234,714.19
	16,552,406.85	15,909,609.63
II. Receivables and other assets		
1. Trade receivables	11,409,550.39	12,288,350.04
2. Receivables from affiliated companies	132,606,536.25	57,536,570.06
3. Receivables from joint ventures	8,606.00	2,034,747.99
4. Other assets	6,987,646.63	2,056,476.08
	151,012,339.27	73,916,144.17
	167,564,746.12	**89,825,753.80**
C. Prepaid expenses	**638,086.28**	**557,981.94**
Total assets	**801,598,171.03**	**788,532,494.53**

Equity and liabilities

EUR	30 Sep 2024	30 Sep 2023
A. Equity		
I. Subscribed capital[1]	150,614,616.00	150,614,616.00
II. Capital reserve	491,934,852.78	491,934,852.78
III. Net retained profit	67,346,528.25	50,052,476.32
	709,895,997.03	**692,601,945.10**
B. Provisions		
1. Provisions for pensions and similar obligations	21,966,760.60	20,053,114.96
2. Provisions for taxes	11,564,251.00	11,564,251.00
3. Other provisions	20,126,816.56	24,126,434.22
	53,657,828.16	**55,743,800.18**
C. Liabilities		
1. Advances received on orders	19,637,481.78	20,699,225.47
2. Trade payables	8,936,931.52	9,163,881.60
3. Liabilities to affiliated companies	8,486,561.66	9,337,714.99
4. Liabilities to joint ventures	0.00	7,565.45
5. Other liabilities	983,370.88	978,361.74
	38,044,345.84	**40,186,749.25**
Total equity and liabilities	**801,598,171.03**	**788,532,494.53**

[1] Conditional capital of EUR 25,000k as of 30 September 2024 (previous year: EUR 25,000k).

INCOME STATEMENT FOR THE FINANCIAL YEAR FROM 1 OCTOBER 2023 TO 30 SEPTEMBER 2024

EUR	2023/2024	2022/2023
1. Revenue	164,436,236.96	180,012,886.95
2. Decrease in finished goods and work in progress	-371,830.38	-2,161,359.49
3. Other own work capitalised	0.00	189,767.76
4. Total operating performance	**164,064,406.58**	**178,041,295.22**
5. Other operating income	10,608,291.99	14,718,922.80
6. Cost of materials		
a) Cost of raw materials, consumables, supplies, and of purchased merchandise	-25,448,816.06	-28,110,980.59
b) Cost of purchased services	-22,228,989.38	-22,156,637.15
	-47,677,805.44	**-50,267,617.74**
7. Personnel expenses		
a) Wages and salaries	-48,877,088.56	-47,607,813.76
b) Social security contributions and expenses for retirement benefits	-12,417,211.80	-10,477,171.60
	-61,294,300.36	**-58,084,985.36**
8. Amortisation, depreciation and impairment of intangible fixed assets and property, plant and equipment	-11,611,625.13	-9,009,106.06
9. Other operating expenses	-65,339,152.99	-55,527,752.03
10. Income from investments	60,207,016.39	146,935,237.71
11. Income from long-term loans	1,608,870.47	8,036.41
12. Other interest and similar income	2,876,860.09	495,228.36
13. Impairment of financial assets	-11,100,000.00	-111,450,000.00
14. Interest and similar expenses	-46,237.76	-37,723.39
15. Income taxes	-2,404,078.51	-12,274,571.23
16. Result after taxes	**39,892,245.33**	**43,546,964.69**
17. Other taxes	-6,001.00	-6,821.00
18. Profit for the period	**39,886,244.33**	**43,540,143.69**
19. Profit carried forward	27,460,283.92	6,512,332.63
20. Net retained profit	**67,346,528.25**	**50,052,476.32**

NOTES TO THE ANNUAL FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR 2023/2024

1 GENERAL INFORMATION

The Annual Financial Statements of SCHOTT Pharma AG & Co. KGaA, Mainz ("SCHOTT Pharma KGaA" or the "company") as of 30 September 2024 have been prepared in accordance with the provisions of German commercial law for large corporations (sections 242 et seqq. and 264 et seqq. HGB) and the supplementary provisions of the AktG.

SCHOTT Pharma KGaA is a listed partnership limited by shares under German law (Kommanditgesellschaft auf Aktien, KGaA). The shares of SCHOTT Pharma KGaA are admitted to trading on the Regulated Market of the Frankfurt Stock Exchange and simultaneously admitted to the sub-segment of the Frankfurt Stock Exchange's Regulated Market with additional post-admission listing obligations (Prime Standard). The shares trade with the ticker symbol 1SXP and with ISIN DE000A3ENQ51.

The financial year of SCHOTT Pharma KGaA commences on 1 October and ends on 30 September of the following year.

The Annual Financial Statements are prepared in euros. Amounts for the reporting period are shown in thousands of euros (EUR k) in the Notes to the Annual Financial Statements (the "Notes") unless stated otherwise. To improve transparency, all required disclosures, including "thereof" items, are included in the Notes.

These Annual Financial Statements of SCHOTT Pharma KGaA comprise the Balance Sheet, the Income Statement and the Notes. Pursuant to section 315e HGB, as the parent entity SCHOTT Pharma KGaA prepares Consolidated Financial Statements in accordance with International Financial Reporting Standards (IFRS). The Management Report of SCHOTT Pharma KGaA and the Group Management Report of SCHOTT Pharma Group as of 30 September 2024 are presented combined, in conformity with section 315(5) in conjunction with section 298(2) HGB.

The Income Statement is classified using the nature of expense method pursuant to section 275(2) HGB.

A list of SCHOTT Pharma KGaA's shareholdings is attached to these Notes.

The Annual Financial Statements were prepared on a going concern basis.

2 REGISTRATION INFORMATION

The company has its registered office in Mainz, Germany, and is entered under the name of SCHOTT Pharma AG & Co. KGaA in the commercial register of the local court in Mainz under HRB 51230.

3 ACCOUNTING POLICIES

The following material accounting policies, which were unchanged compared to the previous year, apply for the preparation of the Annual Financial Statements.

Intangible assets acquired for consideration are recognised at cost less accumulated amortisation calculated on a straight-line basis – usually over an expected useful life of three years. Internally-generated intangible assets are not capitalised, exercising the option pursuant to section 248(2) sentence 1 HGB.

If impairment is expected to be permanent and exceeds the usual wear and tear, impairment losses are recognised. Amortisation of additions to intangible assets is charged *pro rata temporis*.

Property, plant and equipment is recognised at cost, less depreciation due to wear and tear if they have a limited life. The straight-line method of depreciation is used as a matter of principle. The following expected useful lives are applied for the depreciation of the various groups of property, plant and equipment:

	Years
Land rights and buildings	10 to 14
Technical equipment and machinery	7 to 15
Other equipment, operating and office equipment	3 to 15

Independently usable movable fixed assets with limited useful lives are fully expensed in the year of acquisition if their individual acquisition or production cost does not exceed EUR 250.00. For convenience, such assets with a cost of more than EUR 250.00 but not exceeding EUR 1,000.00 are also recognised in an annual collective item for tax purposes in the statutory balance sheet and depreciated over a period of five years. After full depreciation, the collective item is presented as a disposal in the Statement of Changes in Fixed Assets.

If impairment is expected to be permanent and exceeds the usual wear and tear, impairment losses are recognised. Depreciation of additions to property, plant and equipment is charged *pro rata temporis*.

The cost of self-constructed property, plant and equipment includes direct costs as well as appropriate portions of the necessary material and production overheads including depreciation, to the extent that this relates to production. Advance payments made on property, plant and equipment are recognised at their nominal value.

Investment grants provided by public-sector authorities to support the acquisition or production of property, plant and equipment are deducted from cost, leading to a corresponding decrease in future depreciation.

Within financial assets, shares in affiliated companies and joint ventures are recognised at cost or at the lower net realisable values if impairment is expected to be permanent. Impairment losses are reversed to a maximum of cost if impairment was charged in previous years, and all or some of the reasons for impairment cease to apply in subsequent periods. Loans to affiliated companies are recognised at their nominal value.

Within inventories, raw materials, consumables and supplies are valued at the lower of average cost calculated as weighted average prices or net realisable value as of the reporting date; inventory range allowances are used in particular due to the turnover rate of inventories.

Finished goods and work in progress are recognised at production cost in accordance with section 255(2) HGB. Production cost includes direct costs and appropriate portions of material and production overheads as well as the share of fixed asset depreciation caused by production. Allowances are recognised to provide for risks resulting from slow-moving goods and reduced usability; the principle of valuation at net realisable value is observed.

Borrowing costs and general administrative expenses are not included in production cost.

Apart from customary retentions of title, inventories are free from third-party rights.

Receivables and other assets are stated at their nominal value; receivables bearing no interest or interest at a below-market rate that are due in more than one year are recognised at their present value. Discounting is performed using an interest rate for the relevant term published by Deutsche Bundesbank. Specific bad debt allowances are recognised to account for identifiable default risks. For general credit risk, a country-specific allowance calculated on a flat-rate basis is recognised and deducted from receivables carried on the Balance Sheet.

Prepaid expenses are recognised in the amounts paid in the current financial year that relate to expenses for a certain period following the reporting date.

Subscribed capital is carried at its nominal value.

Provisions for pensions and similar obligations are recognised for three major pension commitments:

The “P 82 old” and “P 82 new” pension schemes are salary-based pension schemes. Under these schemes, the pension benefit increases by a percentage of pensionable remuneration for each year of eligible service; salary components in excess of the income threshold are given a higher weighting.

The pension scheme “VO 2015” as well as the previously applicable pension scheme “VO 2000”, which was replaced on 1 October 2015, are defined contribution plans with a dynamic benefit contribution. These are building block schemes, within the scope of which a benefit contribution is determined each year which is then converted into a pension building block using actuarial methods. This pension building block is credited to the employee’s individual benefit account. The pension contribution depends on pensionable remuneration and also on SCHOTT AG Group’s pre-tax profits.

The currently valid “VO 2015 NEW” pension scheme, which has been applicable for new entrants since 1 November 2015, is a defined contribution plan with a dynamic benefit contribution. Calculation of the benefit contribution is similar to that of “VO 2015”. This is awarded to the employee as a minimum capital payment and credited to an individualised securities account within the framework of a Contractual Trust Arrangement (CTA).

From 1 October 2025, the “VO 2015 NEW” pension scheme, including transitional arrangements, will also apply for SCHOTT AG employees on 1 November 2015, the date on which “VO 2015 NEW” came into effect (which was prior to the transfer of operations as part of the spin-off). The spin-off was concluded with effect from 1 October 2021 and the Pharma division, along with all rights and obligations, was transferred from SCHOTT AG, Mainz, Germany, to SCHOTT Pharma KGaA.

Pension commitments are determined on the basis of actuarial calculations using the projected unit credit method and biometric calculation bases in accordance with Prof Klaus Heubeck’s Mortality Tables 2018 G. Expected future salary and pension increases are taken into account in calculating the commitments. An annual adjustment of 3.0% (previous year: 3.0%) for salaries and 1.0% (previous year: 1.0%) for pension commitments subject to a guaranteed adjustment, as well as 2.25% (previous year: 2.25%) for all other pension commitments, is currently assumed, based on internal data from previous years and the expected future assessment basis for the development of inflation. The determination of pension commitments also factors in an annual increase in the income threshold of 1.5% (previous year: 1.5%) and an employee turnover rate of 2.0% p.a. (previous year: 2.0%). The ten-year average interest rate to be used as a basis for the valuation of pension commitments in accordance with section 253(2) HGB was 1.87% as of 30 September 2024 (previous year: 1.81%); this is the interest rate for a remaining term of 15 years as determined by Deutsche Bundesbank. The seven-year average interest rate was 1.91% as of 30 September 2024 (previous year: 1.66%).

The plan assets managed in the form of a CTA are offset against the underlying commitments in accordance with section 246(2) sentence 2 HGB. In order to fulfil the company’s pension obligations to employees, funds are invested in separate securities investment funds that are protected against claims by other creditors and are carried at fair value. The resulting net obligation is recognised under provisions.

The pension provisions for employee-funded deferred compensation commitments are also based on the ten-year average interest rate of 1.87% as of 30 September 2024 (previous year: 1.81%), a pension increase of 1.0% (previous year: 1.0%) and an employee turnover rate of 2.0% (previous year: 2.0%). Employer’s pension liability insurance policies taken out for these provisions are pledged to creditors. Accordingly, the obligations and the cash surrender value of the employer’s pension liability insurance policies (fair value) are netted pursuant to section 246(2) sentence 2 HGB.

Tax provisions and other provisions account for all identifiable risks, uncertain obligations and potential losses from pending transactions. They are recognised at the settlement value deemed necessary according to prudent business judgment to fulfil future payment obligations. Future price and cost increases are taken into consideration if there is sufficient objective evidence that such increases will occur. Provisions with a remaining term of more than one year are discounted using the average market interest rate of the past seven financial years for their respective remaining term.

Provisions for anniversary and phased retirement obligations shown under other provisions are valued at the seven-year average interest rate of 1.91% (previous year: 1.66%) calculated by Deutsche Bundesbank. Pursuant to section 246(2) sentence 2 HGB, provisions for phased retirement obligations are offset against the related plan assets.

Liabilities are recognised at their respective settlement values.

To determine deferred taxes arising due to temporary or quasi-permanent differences between the carrying amounts of assets, liabilities, prepaid expenses and deferred income in the statutory accounts and their tax bases or due to tax loss carryforwards, these differences are valued using the company-specific tax rates at the time they reverse; the amounts of any resulting tax charge or benefit are not discounted. Deferred tax assets and liabilities are offset. The option to recognise net deferred tax assets in excess of deferred tax liabilities was not exercised.

Foreign currency receivables and payables are valued in euros using the mid-market spot rate on the transaction date. They are translated at the mid-market spot rate on the reporting date. Losses from exchange rate fluctuations are accounted for, while gains are only recognised if they relate to receivables or payables with a remaining term of up to one year. Both realised and unrealised gains and losses from the translation of foreign currency transactions into local currency are recognised in the Income Statement under “Other operating income” or “Other operating expenses”, as well as in the associated “thereof” items in the Notes.

Revenue from the sale of goods is recognised as soon as the material risks and rewards of ownership have passed to the buyer and the amount of revenue to be recognised can be reliably measured. Revenue from services is recognised as soon as the service has been rendered.

The fair value of derivative financial instruments is determined on the reporting date based on current market data, strictly at the lower of cost or market. Provisions for potential losses are recognised for unrealised losses, while unrealised gains are not accounted for.

4 NOTES TO THE BALANCE SHEET

Fixed assets

The following overview outlines the development of individual fixed asset items for the financial year from 1 October 2023 to 30 September 2024, including depreciation, amortisation and impairment losses for the financial year.

In the reporting year, there were additions to shares in affiliated companies amounting to EUR 15,594k, reflecting a capital increase at our subsidiary SCHOTT Pharma Brasil Ltda., São Paulo, Brazil.

Impairment of shares in affiliated companies recognised in the reporting year in the amount of EUR 11,100k reflected the value adjustment of shares in SCHOTT Pharma USA, Inc., Lebanon, USA, to their lower fair value of EUR 243,730k as of the reporting date. The accumulated impairment of shares in SCHOTT Pharma USA, Inc., Lebanon, USA, recognised as of the reporting date came to EUR 122,550k.

In the reporting year, there were additions to loans to affiliated companies amounting to EUR 4,000k, due to a loan being granted to our subsidiary SCHOTT PHARMA D.O.O. JAGODINA, Jagodina, Serbia. Because of its three-year term, the loan is recognised within fixed assets. The disposal of EUR 103,510k is due to the repayment of a loan by our subsidiary SCHOTT Pharma Schweiz AG, St Gallen, Switzerland, in the reporting year.

Additions to advance payments made and assets under construction were almost entirely attributable to our manufacturing location in Müllheim; they are predominantly related to capacity expansion projects for the production of polymer syringes.

Statement of Changes in Fixed Assets for the financial year from 1 October 2023 to 30 September 2024

EUR	Cost					Accumulated amortisation, depreciation and impairment				Carrying amounts	
	Balance as of 1 Oct 2023	Additions	Reclassifications	Disposals	Balance as of 30 Sep 2024	Balance as of 1 Oct 2023	Additions	Disposals	Balance as of 30 Sep 2024	30 Sep 2024	30 Sep 2023
I. Intangible fixed assets											
1. Purchased concessions, industrial property rights and similar rights and assets, as well as licences in such rights and assets	1,648,207.91	33,733.35	21,807.10	-5,579.49	1,698,168.87	-1,266,251.60	-256,138.34	5,579.49	-1,516,810.45	181,358.42	381,956.31
	1,648,207.91	**33,733.35**	**21,807.10**	**-5,579.49**	**1,698,168.87**	**-1,266,251.60**	**-256,138.34**	**5,579.49**	**-1,516,810.45**	**181,358.42**	**381,956.31**
II. Property, plant and equipment											
1. Land, land rights and buildings	7,737,516.58	482,410.30	4,932,232.04	-56,729.17	13,095,429.75	-1,529,695.39	-1,071,910.14	30,891.31	-2,570,714.22	10,524,715.53	6,207,821.19
2. Technical equipment and machinery	84,672,840.31	9,900,053.58	10,270,658.73	-878,923.62	103,964,629.00	-44,710,939.08	-7,340,539.53	876,221.26	-51,175,257.35	52,789,371.65	39,961,901.23
3. Other equipment, operating and office equipment	21,384,875.21	1,576,268.57	3,681,436.27	-763,492.52	25,879,087.53	-10,557,531.28	-2,943,037.12	682,832.78	-12,817,735.62	13,061,351.91	10,827,343.93
4. Advance payments made and assets under construction	53,102,568.43	29,990,916.54	-18,906,134.14	0.00	64,187,350.83	0.00	0.00	0.00	0.00	64,187,350.83	53,102,568.43
	166,897,800.53	**41,949,648.99**	**-21,807.10**	**-1,699,145.31**	**207,126,497.11**	**-56,798,165.75**	**-11,355,486.79**	**1,589,945.35**	**-66,563,707.19**	**140,562,789.92**	**110,099,634.78**
III. Financial assets											
1. Shares in affiliated companies	591,413,676.27	15,594,047.54	0.00	0.00	607,007,723.81	-111,450,000.00	-11,100,000.00	0.00	-122,550,000.00	484,457,723.81	479,963,676.27
2. Loans to affiliated companies	103,510,024.95	4,000,000.00	0.00	-103,510,024.95	4,000,000.00	0.00	0.00	0.00	0.00	4,000,000.00	103,510,024.95
3. Joint ventures	4,193,466.48	0.00	0.00	0.00	4,193,466.48	0.00	0.00	0.00	0.00	4,193,466.48	4,193,466.48
	699,117,167.70	**19,594,047.54**	**0.00**	**-103,510,024.95**	**615,201,190.29**	**-111,450,000.00**	**-11,100,000.00**	**0.00**	**-122,550,000.00**	**492,651,190.29**	**587,667,167.70**
	867,663,176.14	**61,577,429.88**	**0.00**	**-105,214,749.75**	**824,025,856.27**	**-169,514,417.35**	**-22,711,625.13**	**1,595,524.84**	**-190,630,517.64**	**633,395,338.63**	**698,148,758.79**

Receivables and other assets

Receivables and other assets are broken down as follows:

(in EUR k)	30 Sep 2024	30 Sep 2023
Trade receivables	11,410	12,288
(thereof due in more than one year)	0	0
Receivables from affiliated companies	132,607	57,537
(thereof due in more than one year)	0	0
Receivables from joint ventures	9	2,035
(thereof due in more than one year)	0	0
Other assets	6,988	2,056
(thereof due in more than one year)	0	0
	151,012	**73,916**

Receivables from affiliated companies as of 30 September 2024 comprised trade receivables of EUR 23,153k (previous year: EUR 34,824k) and the cash pool receivable from SCHOTT AG (EUR 109,454k; previous year: EUR 923k). Receivables in the previous year had also included dividend receivables amounting to EUR 21,790k.

Receivables from joint ventures included dividend receivables of EUR 2,000k in the previous year.

Other assets of EUR 6,988k (previous year: EUR 2,056k) essentially relate to value-added tax and income tax refund claims for the financial year 2023/2024.

Deferred tax assets

Material deferred tax assets and liabilities arise from different carrying amounts of non-current pension provisions as well as other provisions. Overall, deferred tax assets more than offset deferred tax liabilities. The resulting net deferred tax asset is not recognised, exercising the option provided by section 274(1) sentence 2 HGB.

Deferred taxes were measured using a tax rate of 28.3% (previous year: 28.3%).

Equity

Subscribed capital totalled EUR 150,615k and the capital reserve amounted to EUR 491,935k as of the reporting date.

As of the reporting date, subscribed capital was divided into 150,614,616 ordinary bearer shares with no-par value and a notional interest of EUR 1.00 each in the share capital. All shares are fully paid-in.

The Annual General Meeting on 20 June 2023 authorised the Management Board, with the approval of the Supervisory Board, to increase the share capital of SCHOTT Pharma KGaA, until 19 June 2028 by up to a total of EUR 50,000k through one or more issues of new no-par value bearer shares in exchange for cash or non-cash contributions (Authorised Capital). Shareholders will generally be granted subscription rights.

The Annual General Meeting on 20 June 2023 also authorised the Management Board, with the approval of the Supervisory Board, to issue bearer and/or registered convertible bonds and/or bonds with warrants (or a combination of such instruments – hereinafter collectively referred to as “bonds”) with a total principal amount of up to EUR 750,000k, with or without a limited term, on one or several occasions until 19 June 2028 and to grant holders or creditors of such bonds conversion or option rights, respectively, to acquire new no-par value bearer shares in the company representing a notional interest in the share capital of up to EUR 25,000k, as stipulated in detail in the terms and conditions of these bonds (Conditional Capital).

The Management Board did not make use of these authorisations in the financial year 2023/2024.

The Annual General Meeting on 14 March 2024 resolved to appropriate the previous year’s net retained profit (Bilanzgewinn) of EUR 50,052k to distribute dividends of EUR 22,592k (EUR 0.15 per no-par value share) and to carry forward the remainder of EUR 27,460k to new account.

The following table summarises the development of net retained profit:

(in EUR k)	2023/2024
Net retained profit as of 1 October 2023	50,052
Dividends for the financial year 2022/2023	-22,592
Profit for the period – financial year 2023/2024	39,887
Net retained profit as of 30 September 2024	**67,347**

Disclosures on non-distributable amounts

The table below summarises the determination of the maximum distributable amount considering sections 253(6) sentence 2 and 268(8) HGB:

(in EUR k)	30 Sep 2024
Net retained profit as of 30 September 2024	67,347
= Maximum distributable amount as of 30 September 2024 before consideration of sections 253(6) sentence 2 and 268(8) HGB	**67,347**
– Non-distributable amount due to the difference between the 10-year average interest rate and the 7-year average interest rate	0
– Non-distributable amount due to the measurement of assets at fair value	-447
= Maximum distributable amount as of 30 September 2024 considering sections 253(6) sentence 2 and 268(8) HGB	**66,900**

The difference in accordance with section 253(6) sentence 2 HGB between the amount of pension provisions discounted at the relevant average market interest rate for the last ten financial years and the amount of pension provisions discounted at the average market interest rate for the last seven financial years amounts to EUR -262k. As the pension provision calculated based on the average interest rate for the last ten years exceeds the amount calculated based on the average interest rate for the last seven years, there is no ban on distributions.

Pursuant to section 268(8) HGB, an amount of EUR 447k is subject to a ban on distributions as the fair value of the plan assets exceeds their cost. The resulting book gain comes to EUR 624k. Deferred tax liabilities of EUR 177k were deducted from this amount.

Provisions for pensions and similar commitments

Pension provisions include commitments from current pensions as well as company- and employee-funded pension entitlements.

Assets which serve exclusively to fulfil the pension commitments and which are protected against claims asserted by all other creditors (plan assets as defined by section 246(2) sentence 2 HGB) are recognised at fair value and offset against the settlement value of pension commitments.

Amounts offset in the Balance Sheet as of the reporting date:

(in EUR k)	30 Sep 2024	30 Sep 2023
Settlement value of pensions and similar obligations	34,302	30,352
Fair value of plan assets	12,335	10,299
Provisions for pensions and similar commitments	**21,967**	**20,053**
Cost of plan assets	11,711	10,825

Plan assets in Germany are managed mainly in the form of a CTA.

Under the CTA, assets are transferred to a trust association, which in turn transfers the funds it receives to another trustee (custodian). This custodian is obliged to manage and invest the funds it receives solely for the company in accordance with an investment management agreement. Investments are made via special fund mandates with external asset managers. These mandates are mixed funds that invest in equities and bonds, and are managed by asset managers in accordance with prescribed investment guidelines, including a defined value protection strategy.

Expenses from changes in the discount rate are recognised under interest and similar expenses. Of the interest portion of EUR 134k (previous year: EUR 234k) included in additions to pension provisions, EUR 551k (previous year: EUR 487k) relates to discounting and EUR -417k (previous year: EUR -253k) from the change in the discount rate. Net income and expenses from plan assets is offset against the interest portion of additions to the corresponding commitment under the net interest result.

The following amounts were offset:

(in EUR k)	2023/2024	2022/2023
Interest portion of additions to pension provisions	134	234
Net income/expenses from plan assets	-1,149	-202
Balance after offsetting	**-1,015**	**32**

Provisions for taxes

This item comprises amounts for taxes in the financial years 2021/2022 and 2022/2023 that have not yet been finally assessed.

Other provisions

Other provisions primarily include amounts for personnel-related commitments as well as provisions for potential losses from derivative financial instruments, provisions for outstanding supplier invoices, provisions for auditing the annual financial statements and provisions for warranties.

In accordance with section 246(2) sentence 2 HGB, provisions for phased retirement obligations were offset against the related plan assets.

Amounts offset in the Balance Sheet as of the reporting date:

(in EUR k)	30 Sep 2024	30 Sep 2023
Settlement value of phased retirement obligations	1,006	680
Fair value of plan assets	-722	-251
Provisions for phased retirement obligations	**284**	**429**
Cost of plan assets	-722	251

Liabilities

Liabilities have the following remaining terms:

	30 Sep 2024				30 Sep 2023			
(in EUR k)	Thereof with a remaining term of up to one year	Thereof with a remaining term of one to five years	Thereof with a remaining term of more than five years	Total	Thereof with a remaining term of up to one year	Thereof with a remaining term of one to five years	Thereof with a remaining term of more than five years	Total
Advances received on orders	4,381	10,308	4,948	19,637	1,127	13,838	5,734	20,699
Trade payables	8,763	174	0	8,937	9,150	14	0	9,164
Liabilities to affiliated companies	8,487	0	0	8,487	9,338	0	0	9,338
Liabilities to joint ventures	0	0	0	0	8	0	0	8
Other liabilities	983	0	0	983	978	0	0	978
(thereof for taxes)	(748)	0	0	(748)	(631)	0	0	(631)
(thereof for social security)	(60)	0	0	(60)	(5)	0	0	(5)
	22,614	**10,482**	**4,948**	**38,044**	**20,601**	**13,852**	**5,734**	**40,187**

All of the liabilities to affiliated companies relate to trade payables.

As of the reporting date, liabilities to the general partner SCHOTT Pharma Management AG, Mainz, amounted to EUR 342k (previous year: EUR 79k), mainly resulting from the settlement of claims for reimbursement of expenses.

Other liabilities of EUR 983k (previous year: EUR 978k) essentially relate to liabilities from income tax on wages and salaries and church tax.

No liabilities were secured as of the reporting date

5 NOTES TO THE INCOME STATEMENT

Revenue

Revenue is primarily generated from the sale of pharmaceutical packaging; it is broken down by area of activity as follows:

(in EUR k)	2023/2024	2022/2023
Sale of products	87,330	116,048
Contract manufacturing	36,066	24,967
Other	41,040	38,998
	164,436	**180,013**

Revenue from contract manufacturing is fully attributable to contract manufacturing services provided to SCHOTT Pharma Schweiz AG, St Gallen, Switzerland.

Revenue recognised under “Other” mainly arose from rendering services, charging brand licence fees and passing on overhead costs to affiliated companies.

Revenue is broken down by geographical markets as follows:

(in EUR k)	2023/2024	2022/2023
Germany	21,198	23,777
EMEA (excluding Germany	104,273	107,965
Asia and South Pacific	17,852	17,862
North America	17,757	27,046
South America	3,356	3,363
	164,436	**180,013**

Other operating income

Other operating income of EUR 10,608k (previous year: EUR 14,719k) mainly includes currency and exchange rate gains of EUR 6,613k (previous year: EUR 9,381k) as well as income from passing on costs of EUR 2,325k (previous year: EUR 4,442k) to SCHOTT Group companies. Costs passed on were incurred by SCHOTT Pharma KGaA in connection with the IPO and were reimbursed based on a cost assumption agreement entered into in the financial year 2022/2023. Extraordinary income from passing on costs was offset by extraordinary expenses of EUR 2,325k (previous year: EUR 3,946k) in the financial year under review. In the previous year, an additional EUR 496k was related to recharged expenses incurred in the financial year 2021/2022 which thus represented prior-period income.

Additional prior-period income of EUR 1,633k (previous year: EUR 542k) comprises EUR 602k (previous year: EUR 352k) related to the reversal of provisions and EUR 1,031k (previous year: EUR 190k) related to the reversal of loss allowance on receivables. Income from the reversal of provisions relates to various individual items.

Personnel expenses

EUR 4,054k (previous year: EUR 2,867k) of the personnel expenses reported relate to expenses for retirement benefits. The interest portion of additions to pension provisions is not recognised as personnel expenses; this is presented under the net interest result.

Amortisation, depreciation and impairment of intangible fixed assets and property, plant and equipment

As in the previous year, amortisation of intangible fixed assets and depreciation of property, plant and equipment do not include any impairment losses.

Other operating expenses

Other operating expenses include EUR 28,358k (previous year: EUR 29,125k) in selling, general administrative and maintenance expenses, EUR 19,386k (previous year: EUR 14,347k) in expenses for services and EUR 5,309k (previous year: EUR 4,876k) in lease expenses.

Other operating expenses include EUR 345k (previous year: EUR 95k) in additions to other provisions, EUR 3,215k (previous year: EUR 1,103k) in loss allowance on receivables and EUR 93k (previous year: EUR 48k) in prior-period unrealised losses on the disposal of property, plant and equipment.

In addition, currency and exchange rate losses of EUR 8,633k (previous year: EUR 5,933k) were reported as other operating expenses.

Income from investments

Income from investments of EUR 57,957k (previous year: EUR 142,935k) resulted from dividend income received from affiliated companies in Switzerland, Brazil, Indonesia and Colombia; EUR 2,250k (previous year: EUR 4,000k) related to dividend income received from our joint venture in Italy.

Income from long-term loans

Income from long-term loans is attributable in full to the loans granted to affiliated companies in Switzerland and Serbia.

Impairment of financial assets

The impairment of financial assets of EUR 11,100k (previous year: EUR 111,450k) reflected the value adjustment of shares in SCHOTT Pharma USA, Inc., Lebanon, USA, to their lower fair value.

Net interest result

(in EUR k)	**2023/2024**	**2022/2023**
Other interest and similar income	2,877	495
(thereof from affiliated companies)	1,850	485
(thereof expenses from discounting)	-134	0
(thereof net income/expenses from plan assets)	1,149	0
Interest and similar expenses	-46	-38
(thereof to affiliated companies)	-34	0
(thereof expenses from discounting)	0	-234
(thereof net income/expenses from plan assets)	0	202

Net income and expenses from plan assets is offset against the interest portion of additions to the corresponding commitment in the net interest result.

Income taxes

Income taxes amounting to EUR 2,404k (previous year: EUR 12,275k) mainly relate to trade and corporation tax as well as foreign withholding taxes for the financial year 2023/2024.

Income taxes do not include any income or expenses from deferred taxes.

The act for ensuring a global minimum level of taxation for corporate groups came into force in Germany on 28 December 2023. As a domestic constituent entity and partially-owned parent entity (POPE), SCHOTT Pharma KGaA belongs to its ultimate parent entity (UPE) SCHOTT AG, which, due to its tax domicile in Germany, falls within the scope of this act. Since the act applies in principle to all financial years beginning after 30 December 2023, it will take effect for SCHOTT Pharma KGaA for the first time in the financial year 2024/2025.

As UPE of SCHOTT Group, SCHOTT AG is obliged to submit the legally required minimum tax return, to calculate the tax and, if necessary, to pay any top-up taxes. This also includes those calculations that relate to SCHOTT Pharma KGaA as the POPE and the domestic and foreign constituent entities it holds. The minimum rate of tax within the meaning of the act is 15%.

Where top-up taxes arise for jurisdictions that concern SCHOTT Pharma KGaA or one of its constituent entities and that have not already been settled through the payment of qualified domestic top-up taxes, these are charged by SCHOTT AG to SCHOTT Pharma KGaA. These allocations are to be included as income taxes in the financial statements of SCHOTT Pharma KGaA.

SCHOTT Pharma KGaA has performed a corresponding impact analysis for SCHOTT Pharma Group. If the provisions on the global minimum tax were to be applied in the financial year 2023/2024 – based on the current assessment and taking into account the temporary safe-harbour regulations – it would result in an approximately EUR 2.5m increase in the current taxes of SCHOTT Pharma Group, originating exclusively from Switzerland. As Switzerland is introducing qualified domestic top-up taxes, we do not expect to see any top-up taxes attributable to SCHOTT Pharma KGaA based on the information that is currently available.

Tax effects that may arise from the future application of the global minimum tax rules are not taken into account when calculating the recognition of deferred tax assets and liabilities.

6 OTHER INFORMATION

Derivative financial instruments

The company held the following derivative financial instruments as of the reporting date:

(in EUR k)	30 Sep 2024 Nominal amount	30 Sep 2024 Carrying amount	30 Sep 2024 Fair value
Forward foreign exchange contracts	411,538	-4,353	-1,127

Nominal amounts reflect the unnetted total of all derivative financial contracts bought and sold. The carrying amount is the lower of cost or fair value. Negative carrying amounts of forward contracts are included in the Balance Sheet item “Other provisions.” The fair value of the forward foreign exchange contracts is determined using current spot rates and corresponding forward premiums or discounts (spreads). The relevant market data observed on the reporting date are used as input parameters for the models. Forward transactions were concluded primarily in US dollars (USD), Swiss francs (CHF), Chinese renminbi (CNY), Hungarian forint (HUF) and Mexican pesos (MXN).

Contingencies

The following contingent liabilities existed as of the reporting date:

(in EUR k)	30 Sep 2024	30 Sep 2023
Guarantees	39,624	39,344
(thereof in favour of affiliated companies)	38,264	37,985

Together with SCHOTT Group Treasury, SCHOTT Pharma KGaA’s Finance department continuously monitors and assesses contingent liabilities entered into. As of 30 September 2024, and up to the date of preparation of the Annual Financial Statements, the Management Board assumes that the respective principal debtors will honour their obligations. This assessment is based on the expected positive business performance or the sufficient capitalisation of the companies concerned.

The risk of drawdowns on contingent liabilities was deemed to be low.

Other financial obligations

Expenses from rental and lease agreements for land, buildings, technical equipment and operating equipment as well as from significant service agreements totalled EUR 6,345k (previous year: EUR 5,682k) in the financial year, of which EUR 3,991k (previous year: EUR 3,875k) was attributable to affiliated companies. The expected future minimum payments from existing rental and lease agreements and significant service agreements totalled EUR 36,735k as of the reporting date (thereof EUR 6,013k for the following twelve months); this includes EUR 34,852k (thereof EUR 4,203k for the following twelve months) to affiliated companies.

As of the reporting date, obligations from purchase commitments for investment projects amounted to EUR 21,569k (previous year: EUR 41,771k), of which EUR 1,840k (previous year: EUR 605k) related to affiliated companies.

Other financial obligations thus totalled EUR 58,304k (previous year: EUR 81,164k), of which EUR 36,692k (previous year: EUR 38,472k) related to affiliated companies.

Off-balance sheet transactions

For information on off-balance sheet transactions, please refer to our explanations on other financial obligations.

Rental and lease agreements gave rise to payment obligations of EUR 36,735k (previous year: EUR 39,393k) as of the reporting date. The terms of these agreements expire between the financial years 2024/2025 and 2031/2032. These rental and lease agreements generally serve to improve liquidity and reduce total assets. Rental and lease agreements concluded at customary conditions do not give rise to any specific risks.

Average number of employees

The average number of people employed by SCHOTT Pharma KGaA in the financial year was as follows:

	2023/2024	**2022/2023**
Wage earners	398	387
Salaried employees	282	251
	680	**638**

Auditor’s fee

The auditor of the Annual Financial Statements of SCHOTT Pharma KGaA and SCHOTT Pharma Group is EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft, Eschborn/Frankfurt am Main (EY). The auditing fees related primarily to the audit of the Consolidated Financial Statements of SCHOTT Pharma KGaA, audits of the Annual Financial Statements of SCHOTT Pharma KGaA and its subsidiaries, and the review of the Condensed Interim Consolidated Financial Statements as of 31 March 2024. Other assurance services related mainly to other assurance services required by law, contractually agreed or commissioned on a voluntary basis.

In the financial year 2022/2023, the auditing fees also included the fees for the audit of the Combined Financial Statements for the financial years 2019/2020, 2020/2021 and 2021/2022 in connection with the IPO, whilst fees incurred for the issue of the comfort letter are shown under other assurance services. These fees were refunded by SCHOTT Group companies in the financial year 2022/2023 based on a cost assumption agreement, with the corresponding income reported in other operating income.

The disclosures on the fee paid to the auditor, pursuant to section 285 no. 17 HGB, for services rendered to SCHOTT Pharma KGaA are included in the Notes to the Consolidated Financial Statements of SCHOTT Pharma KGaA.

Remuneration of the Management Board and the Supervisory Board

Remuneration of the members of the Management Board totalled EUR 1,524k in the financial year 2023/2024 (previous year: EUR 1,248k). This includes EUR 65k in share-based remuneration as part of the LTI programme that the company introduced in the financial year 2023/2024. The tranche granted in the financial year 2023/2024 includes the performance period from 1 October 2023 to 30 September 2027 and is based on a total of 16,307 allocated performance shares.

The remuneration of the members of the Supervisory Board comprises a fixed remuneration as well as additional remuneration for work in committees and amounted to EUR 340k in the financial year 2023/2024 (previous year: EUR 132k)

The basic principles of the remuneration system and individual remuneration amounts for members of the Management Board and the Supervisory Board are summarised in the Remuneration Report.

The obligation for paying remuneration to the Management Board members lies with SCHOTT Pharma Management AG. SCHOTT Pharma Management AG, however, is entitled to receive compensation from SCHOTT Pharma KGaA for all expenses associated with the management of the company's business, including the remuneration paid to members of its executive bodies. Accordingly, remuneration for the members of SCHOTT Pharma Management AG's Management Board and Supervisory Board was charged to SCHOTT Pharma KGaA. As this means that SCHOTT Pharma KGaA bears the obligation in financial terms and effectively benefits from the work of the Management Board members, all provisions and prepaid expenses related to Management Board remuneration were also recognised at the level of SCHOTT Pharma KGaA.

Andreas Reisse has two plans structured as a direct commitment granted by SCHOTT Pharma KGaA, which have been maintained by this company as statutory non-forfeitable entitlements since 30 September 2023. There are no further entitlements under these plans, and no further entitlements have been earned since 30 September 2023. Provisions stood at EUR 2,931k as of 30 September 2024 (previous year: EUR 2,909k).

No loans or advances were granted, or subsidies paid, to members of the Management Board or the Supervisory Board. Furthermore, the company has not entered into any contingent liabilities in favour of members of the Management Board or the Supervisory Board.

Related party transactions

No significant transactions with related parties were entered into on terms other than arm's length.

General partner

SCHOTT Pharma Management AG, having its registered office in Mainz and subscribed capital of EUR 50k, is the general partner of SCHOTT Pharma KGaA.

Consolidated Financial Statements

As the parent company, SCHOTT AG, Hattenbergstrasse 10, 55122 Mainz, Germany, prepares Consolidated Financial Statements as of 30 September 2024 for the largest group of consolidated companies, in which SCHOTT Pharma KGaA is included. These Consolidated Financial Statements are published online and in the German Company Register (Unternehmensregister).

Pursuant to section 315e(1) HGB, as the parent company, SCHOTT Pharma KGaA prepares Consolidated Financial Statements for the smallest group of consolidated companies based on International Financial Reporting Standards (IFRS) as adopted by the European Union. The Annual Financial Statements, the Management Report of SCHOTT Pharma KGaA (which is combined with the Group Management Report) and the Consolidated Financial Statements of SCHOTT Pharma KGaA are published in the electronic Company Register; in addition, they are available on our website at https://ir.schott-pharma.com/investor-relations/news-publications/reports-and-presentations/.

Declaration of Compliance pursuant to section 161 AktG

The Management Board and the Supervisory Board issued the Declaration of Compliance pursuant to section 161 AktG in September 2024 and subsequently made it permanently available to the public on the website of SCHOTT Pharma KGaA, at https://ir.schott-pharma.com/investor-relations/corporate-governance/compliance-statement/.

Notifications of shareholdings in SCHOTT Pharma AG & Co. KGaA

As of 30 September 2024, SCHOTT Pharma KGaA had received notifications regarding shareholdings subject to disclosure requirements pursuant to section 160(1) no. 8 AktG as shown in the following table. Where multiple voting rights thresholds were reached, the most recent notification which led to a threshold being reached is shown. All voting rights notifications can be viewed on our website at https://www.schott-pharma.com/investor-relations/share/voting-rights-notifications/. Please note that the disclosures on shareholdings and voting rights may have become outdated in the meantime.

Shareholder structure

Entity subject to the reporting obligation	Registered office	Date of notification	Date of threshold being reached	Threshold in %	Share of voting rights in %	Share of voting rights in absolute terms	Voting rights attributable pursuant to the German Securities Trading Act (WpHG)
SCHOTT Glaswerke Beteiligungs- und Export GmbH	Mainz, Germany	28 Sep 2023	27 Sep 2023	75.0%	77.00%	115,973,254	Sections 33 and 34 WpHG
State of Qatar	Doha, Qatar	3 Oct 2023	2 Oct 2023	3.0%	4.92%	7,407,407	Sections 33 and 34 WpHG
The Capital Group Companies, Inc.	Los Angeles, USA	21 Jun 2024	20 Jun 2024	3.0%	3.31%	4,981,834	Sections 33, 34, 38 WpHG
T. Rowe Price Group, Inc.	Baltimore, USA	27 Sep 2024	25 Sep 2024	3.0%	2.78%	4,187,956	Sections 33, 34, 38 WpHG

Appropriation of profits

Net retained profit for the financial year 2023/2024 totalled EUR 67,347k. The Supervisory Board and the Management Board propose to the Annual General Meeting to distribute a dividend of EUR 0.16 per no-par value share (corresponding to a total dividend distribution of EUR 24,098k) and to carry forward the remaining net retained profit of EUR 43,249k.

Report on material events after the reporting date

Dr. Wolfgang Wienand will resign from the Supervisory Board of SCHOTT Pharma KGaA with effect from 31 December 2024. Prof. Dr. Wolfram Carius from Mainz, Germany, is to be put forward to the Annual General Meeting as a potential successor when it is held on 4 February 2025.

No other significant events occurred between the reporting date (30 September 2024) and the date on which this report was prepared (10 December 2024) that would have had a material effect on the financial position and financial performance of SCHOTT Pharma KGaA.

7 EXECUTIVE BODIES OF THE COMPANY

Management Board of SCHOTT Pharma Management AG, general partner of SCHOTT Pharma AG & Co. KGaA

Andreas Reisse

Chairman of the Management Board of SCHOTT Pharma Management AG

(on the Management Board since 15 July 2022)

Offices held:

Member of the Board of Directors, SCHOTT Glass Technologies Co. Ltd., Suzhou, China

Chairman and Legal Representative of the Board of Directors, SCHOTT Pharmaceutical Packaging Co. Ltd., Zhejiang, China

Chairman of the Board of Directors, SCHOTT Poonawalla Pvt. Ltd., Mumbai, India

Dr. Almuth Steinkühler

Member of the Management Board (CFO) of SCHOTT Pharma Management AG

(on the Management Board since 15 July 2022)

Offices held:

Chairman of the Board of Directors, SCHOTT Poonawalla Pvt. Ltd., Mumbai, India

Supervisory Board of SCHOTT Pharma AG & Co. KGaA

Peter Goldschmidt

Chief Executive Officer,
STADA Arzneimittel AG, Bad Vilbel, Germany

Chairman of the Supervisory Board of SCHOTT Pharma AG & Co. KGaA

(on the Supervisory Board since 4 April 2023)

Offices held:

Member of the Supervisory Board, SCHOTT Pharma Management AG, Mainz, Germany

Dr. Wolfgang Wienand

Chief Executive Officer,
Lonza AG, Basel, Switzerland (since July 2024)

Chief Executive Officer, Siegfried Holding AG, Zofingen, Switzerland (until June 2024)

Deputy Chairman of the Supervisory Board of SCHOTT Pharma AG & Co. KGaA

(on the Supervisory Board since 4 April 2023)

Offices held:

Member of the Board of Directors, Mettler-Toledo International Inc., Columbus, USA

Member of the Supervisory Board, SCHOTT Pharma Management AG, Mainz, Germany

Ann-Kristin Erkens

Chief Financial Officer,
SIG Group AG, Neuhausen, Switzerland

(on the Supervisory Board since 4 April 2023)

Eva Kienle

Chief Financial Officer,
KWS SAAT SE & Co. KGaA, Einbeck, Germany

(on the Supervisory Board since 4 April 2023)

Offices held:

Member of the Supervisory Board, Zumtobel Group AG, Dornbirn, Austria

Christine Wening

Head of Global Supply Chain Management

Employee representative

(on the Supervisory Board since 19 April 2023)

Mario Just

Member of the Employee Council

Employee representative

(on the Supervisory Board since 19 April 2023)

Audit Committee

- Eva Kienle, Chairwoman
- Ann-Kristin Erkens
- Christine Wening

Mainz, Germany, 10 December 2024

SCHOTT Pharma AG & Co. KGaA
represented by the Management Board of SCHOTT Pharma Management AG

Andreas Reisse

Dr. Almuth Steinkühler

LIST OF DIRECT AND INDIRECT SHAREHOLDINGS OF SCHOTT PHARMA AG & CO. KGAA AS OF 30 SEPTEMBER 2024 IN ACCORDANCE WITH SECTION 285(1) NO. 11 HGB

Name and registered office of the company	Shareholding (section 285 no. 11 HGB)	Local currency	IFRS equity Local currency	IFRS equity EUR *)	IFRS result after taxes Local currency	IFRS result after taxes EUR **)
	in %	(Local currency)	in k	in k	in k	in k
Affiliated companies						
Germany						
SCHOTT Pharma Mexico GmbH, Mainz, Germany	100.0	EUR	40,762	40,762	18	18
International						
SCHOTT Envases Argentina S.A., Buenos Aires, Argentina	100.0	ARS	10,450,624	9,643	-2,714,130	-2,504
SCHOTT Pharma Brasil Ltda., São Paulo, Brazil	100.0	BRL	174,181	28,614	27,852	5,103[1]
SCHOTT Pharmaceutical Packaging (Zhejiang) Co., Ltd., Huzhen Town, China	100.0	CNY	429,386	54,778	12,668	1,644[1]
SCHOTT France Pharma Systems SAS, Pont-sur-Yonne, France	100.0	EUR	-1,789	-1,789	-597	-597
SCHOTT Pharma France SAS, Colombes, France	100.0	EUR	10,265	10,265	510	510
PT. SCHOTT Igar Glass, Bekasi, Indonesia	100.0	IDR	411,740,490	24,264	167,809,922	9,854
SCHOTT Envases Farmacéuticos SAS, Bogotá, Colombia	72.7	COP	31,756,265	6,820	10,394,726	2,415[1]
SCHOTT de México, S.A. de C.V., Amatlán de los Reyes, Mexico	100.0	MXN	1,307,756	59,795	142,883	7,726[1]
SCHOTT Pharmaceutical Packaging OOO, Zavolzhye, Russia	100.0	RUB	849,762	8,196	274,757	2,740[1]
SCHOTT forma vitrum holding ag, St Gallen, Switzerland	100.0	CHF	63,727	47,737	13,932	14,778
SCHOTT Pharma Schweiz AG, St Gallen, Switzerland	100.0	CHF	254,650	259,692	124,695	130,182
SCHOTT Hungary Kft., Lukácsháza, Hungary	100.0	HUF	11,907,302	29,990	-1,838,468	-4,755
SCHOTT Pharma USA, Inc., Lebanon, USA	100.0	USD	78,593	70,329	17,814	16,423
SCHOTT Pharma D.O.O. JAGODINA (formerly SCHOTT Pharma D.O.O. BEOGRAD Belgrade,), Jagodina, Serbia	100.0	RSD	1,111,333	9,495	-387,559	-3,309
Joint ventures						
International						
SCHOTT Poonawalla Pvt. Ltd., Mumbai, India	50.0	INR	12,042,596	128,429	1,855,144	20,582[2]
Empha S.p.A., Turin, Italy	50.0	EUR	15,611	15,611	4,030	4,030[1]
Smart Skin Technologies Inc., Fredericton, Canada	20	CAD	10,094	6,890	-804	-544[1]

[1] Financial year from 1 January to 31 December
[2] Financial year from 1 April to 31 March
*) For companies whose accounts are in foreign currency, equity is converted using the prevailing exchange rate on the respective reporting date.
**) For companies whose accounts are in foreign currency, profit/loss for the period is converted using the average exchange rate for the period ending on the respective reporting date.

RESPONSIBILITY STATEMENT

To the best of our knowledge, and in accordance with the applicable accounting principles, the Annual Financial Statements give a true and fair view of the assets, liabilities, financial position and profit or loss of SCHOTT Pharma AG & Co. KGaA, and the company's Management Report, which is combined with the Group Management Report, includes a fair review of the development and performance of the business and the position of the company, together with a description of the principal opportunities and risks associated with the expected development of SCHOTT Pharma AG & Co. KGaA.

Mainz, 10 December 2024

SCHOTT Pharma AG & Co. KGaA
represented by the Management Board of SCHOTT Pharma Management AG

Andreas Reisse

Dr Almuth Steinkühler

INDEPENDENT AUDITOR'S REPORT

To SCHOTT Pharma AG & Co. KGaA

REPORT ON THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS AND OF THE COMBINED MANAGEMENT REPORT

OPINIONS

We have audited the annual financial statements of SCHOTT Pharma AG & Co. KGaA, Mainz, which comprise the balance sheet as at September 30, 2024, and the income statement for the fiscal year from October 1, 2023 to September 30, 2024, and notes to the financial statements, including the recognition and measurement policies presented therein. In addition, we have audited the management report of SCHOTT Pharma AG & Co. KGaA, which is combined with the group management report of SCHOTT Pharma AG & Co. KGaA ("combined management report") for the fiscal year from October 1, 2023 to September 30, 2024. In accordance with the German legal requirements, we have not audited the content of the combined non-financial statement included in the "Non-financial statement" section of the combined management report or the corporate governance statement, which is published on the website stated in the combined management report and is part of the combined management report. Furthermore, we have not audited the content of the disclosures extraneous to management reports contained in the third paragraph of the "Group-wide management of risks and opportunities" subsection of the "Report on risks and opportunities" section. Disclosures extraneous to management reports are such disclosures that are not required pursuant to Secs. 289 to 289f and 315 to 315d HGB or pursuant to GAS 20.

In our opinion, on the basis of the knowledge obtained in the audit,

- the accompanying annual financial statements comply, in all material respects, with the requirements of German commercial law applicable to business corporations and give a true and fair view of the assets, liabilities and financial position of the Company as at September 30, 2024 and of its financial performance for the fiscal year from October 1, 2023 to September 30, 2024 in compliance with German legally required accounting principles, and
- the accompanying combined management report as a whole provides an appropriate view of the Company's position. In all material respects, this combined management report is consistent with the annual financial statements, complies with German legal requirements and appropriately presents the opportunities and risks of future development. We do not express an opinion on the content of the combined non-financial statement referred to above, on the content of the corporate governance statement referred to above or on the content of the aforementioned third paragraph of the "Group-wide management of risks and opportunities" subsection of the "Report on risks and opportunities" section of the combined management report.

Pursuant to Sec. 322 (3) Sentence 1 HGB ["Handelsgesetzbuch": German Commercial Code], we declare that our audit has not led to any reservations relating to the legal compliance of the annual financial statements and of the combined management report.

BASIS FOR THE OPINIONS

We conducted our audit of the annual financial statements and of the combined management report in accordance with Sec. 317 HGB and the EU Audit Regulation (No 537/2014, referred to subsequently as "EU Audit Regulation") and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer [Institute of Public Auditors in Germany] (IDW). Our responsibilities under those requirements and principles are further described in the "Auditor's responsibilities for the audit of the annual financial statements and of the combined management report" section of our auditor's report. We are independent of the Company in accordance with the requirements of European law and German commercial and professional law, and we have fulfilled our other German professional responsibilities in accordance with these requirements. In addition, in accordance with Art. 10 (2) f) of the EU Audit Regulation, we declare that we have not provided non-audit services prohibited under Art. 5 (1) of the EU Audit Regulation. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions on the annual financial statements and on the combined management report.

KEY AUDIT MATTERS IN THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the annual financial statements for the fiscal year from October 1, 2023 to September 30, 2024. These matters were addressed in the context of our audit of the annual financial statements as a whole, and in forming our opinion thereon; we do not provide a separate opinion on these matters.

Below, we describe what we consider to be the key audit matters:

1. Revenue recognition, in particular with regard to correct revenue recognition prior to the reporting date

Reasons why the matter was determined to be a key audit matter

In the annual financial statements of SCHOTT Pharma AG & Co. KGaA, revenue from the sale of products is recognized when control of the products has been transferred. This is usually the case when risks have been transferred in accordance with the agreed Incoterms.

Due to the large number of customers, the different types of products and the resulting large number of different contractual arrangements, including those governing the transfer of risk, particular care is required when accounting for transactions, especially with regard to the correct application of the accrual basis of accounting. Against this background, revenue recognition, in particular with regard to correct revenue recognition prior to the reporting date, was a key audit matter.

Auditor's response

During our audit, we considered, based on the requirements of German commercial law, the recognition and measurement requirements applied in the annual financial statements of SCHOTT Pharma AG & Co. KGaA for the recognition of revenue. Furthermore, we obtained an understanding of the design of the underlying business processes and tested the design and operating effectiveness of selected controls of the accounting-related internal control system, in particular with regard to changes in Incoterms and the correct application of the accrual basis of accounting for revenue. We analyzed the recognition of revenue based on the contractual arrangements on a sample basis in view of the requirements of German commercial law. To substantiate the existence of revenue, we examined whether it led to trade receivables and, in turn, whether payments were received to settle these receivables. In addition, applying analytical and substantive audit procedures, we analyzed whether the revenue for fiscal year 2023/2024 was recognized on an accrual basis, e.g., by obtaining external balance confirmations for trade receivables and reviewing credit notes issued after the reporting date.

Overall, our procedures on the recognition of revenue from the sale of products, in particular with regard to correct revenue recognition prior to the reporting date, did not lead to any reservations.

Reference to related disclosures

With regard to the recognition and measurement policies applied for the recognition of revenue from the sale of products, refer to the disclosures on revenue in note “3 Accounting policies” and note “5 Notes to the Income Statement” of the notes to the financial statements.

2. Impairment of shares in affiliated companies, in particular in the USA and Mexico

Reasons why the matter was determined to be a key audit matter

SCHOTT Pharma AG & Co. KGaA holds shares in affiliated companies that make up a significant portion of its total assets.

In accordance with Sec. 253 (3) Sentence 5 HGB, write-downs must be recognized on shares in affiliated companies if their impairment is likely to be permanent. The Company tests each year on the basis of the affiliated companies' budgets and forecasts whether there are any indications that a recognized share in an affiliated company could be permanently impaired. The result of this test is highly dependent on how the executive directors of SCHOTT Pharma AG & Co. KGaA expect the business of the respective affiliated company to develop in the future. Furthermore, the shares in affiliated companies in the USA and Mexico were transferred at fair value as part of the legal restructuring of the SCHOTT Pharma Group in fiscal year 2021/2022, as a result of which the risk of impairment due to changes in the underlying budgets and forecasts and valuation inputs, in particular the applicable cost of capital rates, is especially high. In light of the materiality of the shares in affiliated companies in relation to total assets, the complexity of their valuation and the judgment exercised during valuation, the impairment test of the recognized shares in affiliated companies was a key audit matter.

Auditor's response

During our audit, we first considered the measurement requirements applied in the annual financial statements in terms of their compliance with German commercial law. Furthermore, we obtained an understanding of the design of the underlying business processes and identified selected controls of the accounting-related internal control system, and assessed the valuation model used by SCHOTT Pharma AG & Co. KGaA with regard to its fundamental suitability, including in comparison to prior years and in terms of its mathematical accuracy.

We discussed with the executive directors of SCHOTT Pharma AG & Co. KGaA the significant assumptions relating to the general and industry-specific market development and compared them with the results realized in the past and with external data. In addition, we analyzed the inputs used to determine the cost of capital rates applied and reperformed the calculation in view of the relevant requirements of German commercial law. We also performed sensitivity analyses in order to estimate any potential impairment risk associated with a reasonably possible change in one of the significant assumptions used in the valuation. Our procedures on the impairment of shares in affiliated companies were performed with the involvement of internal valuation specialists.

Our procedures did not lead to any reservations relating to the impairment of shares in affiliated companies.

Reference to related disclosures

With regard to the recognition and measurement policies applied for shares in affiliates, refer to the Company's disclosures on financial assets in note "3 Accounting policies," on "Fixed assets" in note "4 Notes to the Balance Sheet" and on "Impairment of financial assets" in note "5 Notes to the Income Statement" of the notes to the financial statements.

OTHER INFORMATION

The executive directors and the Supervisory Board are responsible for the declaration pursuant to Sec. 161 AktG on the German Corporate Governance Code, which is part of the corporate governance statement. In all other respects, the executive directors are responsible for the other information. The other information comprises the combined non-financial statement referred to above, the corporate governance statement referred to above and the aforementioned disclosures extraneous to management reports contained in the third paragraph of the "Group-wide management of risks and opportunities" subsection of the "Report on risks and opportunities" section of the combined management report. The other information also comprises additional parts to be included in the annual report, of which we obtained a copy prior to issuing this auditor's report, in particular:

- Responsibility statement
- All other parts of the published annual report

but not the annual financial statements, not the disclosures in the combined management report whose content is audited and not our auditor's report thereon.

Our opinions on the annual financial statements and on the combined management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon.

In connection with our audit, our responsibility is to read the other information and, in so doing, to consider whether the other information

- is materially inconsistent with the annual financial statements, with the combined management report or our knowledge obtained in the audit, or
- otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF THE EXECUTIVE DIRECTORS AND THE SUPERVISORY BOARD FOR THE ANNUAL FINANCIAL STATEMENTS AND THE COMBINED MANAGEMENT REPORT

The executive directors are responsible for the preparation of the annual financial statements that comply, in all material respects, with the requirements of German commercial law applicable to business corporations, and that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German legally required accounting principles. In addition, the executive directors are responsible for such internal control as they, in accordance with German legally required accounting principles, have determined necessary to enable the preparation of annual financial statements that are free from material misstatement, whether due to fraud (i.e., fraudulent financial reporting and misappropriation of assets) or error.

In preparing the annual financial statements, the executive directors are responsible for assessing the Company's ability to continue as a going concern. They also have the responsibility for disclosing, as applicable, matters related to going concern. In addition, they are responsible for financial reporting based on the going concern basis of accounting, provided no actual or legal circumstances conflict therewith.

Furthermore, the executive directors are responsible for the preparation of the combined management report that, as a whole, provides an appropriate view of the Company's position and is, in all material respects, consistent with the annual financial statements, complies with German legal requirements and appropriately presents the opportunities and risks of future development. In addition, the executive directors are responsible for such arrangements and measures (systems) as they have considered necessary to enable the preparation of a combined management report that is in accordance with the applicable German legal requirements, and to be able to provide sufficient appropriate evidence for the assertions in the combined management report.

The Supervisory Board is responsible for overseeing the Company's financial reporting process for the preparation of the annual financial statements and of the combined management report.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE ANNUAL FINANCIAL STATEMENTS AND OF THE COMBINED MANAGEMENT REPORT

Our objectives are to obtain reasonable assurance about whether the annual financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the combined management report as a whole provides an appropriate view of the Company's position and, in all material respects, is consistent with the annual financial statements and the knowledge obtained in the audit, complies with the German legal requirements and appropriately presents the opportunities and risks of future development, as well as to issue an auditor's report that includes our opinions on the annual financial statements and on the combined management report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Sec. 317 HGB and the EU Audit Regulation and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer (IDW) will always detect a material misstatement. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial statements and this combined management report.

We exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial statements and of the combined management report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than the risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit of the annual financial statements and of arrangements and measures (systems) relevant to the audit of the combined management report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of these systems of the Company.
- Evaluate the appropriateness of accounting policies used by the executive directors and the reasonableness of estimates made by the executive directors and related disclosures.
- Conclude on the appropriateness of the executive directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in the auditor's report to the related disclosures in the annual financial statements and in the combined management report or, if such disclosures are inadequate, to modify our respective opinions. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to be able to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual financial statements, including the disclosures, and whether the annual financial statements present the underlying transactions and events in a manner that the annual financial statements give a true and fair view of the assets, liabilities, financial position and financial performance of the Company in compliance with German legally required accounting principles.
- Evaluate the consistency of the combined management report with the annual financial statements, its conformity with [German] law, and the view of the Company's position it provides.
- Perform audit procedures on the prospective information presented by the executive directors in the combined management report. On the basis of sufficient appropriate audit evidence we evaluate, in particular, the significant assumptions used by the executive directors as a basis for the prospective information, and evaluate the proper derivation of the prospective information from these assumptions. We do not express a separate opinion on the prospective information and on the assumptions used as a basis. There is a substantial unavoidable risk that future events will differ materially from the prospective information.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with the relevant independence requirements, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable, the related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the annual financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter.

OTHER LEGAL AND REGULATORY REQUIREMENTS

Report on the assurance on the electronic rendering of the annual financial statements and the management report prepared for publication purposes in accordance with Sec. 317 (3a) HGB

Opinion

We have performed assurance work in accordance with Sec. 317 (3a) HGB to obtain reasonable assurance about whether the rendering of the annual financial statements and the management report (hereinafter the "ESEF documents") contained in 2024_SCHOTT_Pharma_EA_ESEF.zip and prepared for publication purposes complies in all material respects with the requirements of Sec. 328 (1) HGB for the electronic reporting format ("ESEF format"). In accordance with German legal requirements, this assurance work extends only to the conversion of the information contained in the annual financial statements and the combined management report into the ESEF format and therefore relates neither to the information contained within these renderings nor to any other information contained in the file identified above.

In our opinion, the rendering of the annual financial statements and the combined management report contained in the file identified above and prepared for publication purposes complies in all material respects with the requirements of Sec. 328 (1) HGB for the electronic reporting format. Beyond this assurance opinion and our audit opinions on the accompanying annual financial statements and the accompanying management report for the fiscal year from October 1, 2023 to September 30, 2024 contained in the "Report on the audit of the annual financial statements and of the management report" above, we do not express any assurance opinion on the information contained within these renderings or on the other information contained in the file identified above.

Basis for the opinion

We conducted our assurance work on the rendering of the annual financial statements and the combined management report contained in the file identified above in accordance with Sec. 317 (3a) HGB and the IDW Assurance Standard: Assurance on the Electronic Rendering of Financial Statements and Management Reports Prepared for Publication Purposes in Accordance with Sec. 317 (3a) HGB (IDW AsS 410 (06.2022)). Our responsibility in accordance therewith is further described in the "Auditor's responsibilities for the assurance work on the ESEF documents" section. Our audit firm applies the IDW Standard on Quality Management 1: Requirements for Quality Management in the Audit Firm (IDW QMS 1) (09.2022).

Responsibilities of the executive directors and the Supervisory Board for the ESEF documents

The executive directors of the Company are responsible for the preparation of the ESEF documents including the electronic rendering of the annual financial statements and the management report in accordance with Sec. 328 (1) Sentence 4 No. 1 HGB.

In addition, the executive directors of the Company are responsible for such internal control as they have determined necessary to enable the preparation of ESEF documents that are free from material intentional or unintentional non-compliance with the requirements of Sec. 328 (1) HGB for the electronic reporting format.

The Supervisory Board is responsible for overseeing the process for preparing the ESEF documents as part of the financial reporting process.

Auditor's responsibilities for the assurance work on the ESEF documents

Our objective is to obtain reasonable assurance about whether the ESEF documents are free from material intentional or unintentional non-compliance with the requirements of Sec. 328 (1) HGB. We exercise professional judgment and maintain professional skepticism throughout the assurance work. We also:

- Identify and assess the risks of material intentional or unintentional non-compliance with the requirements of Sec. 328 (1) HGB, design and perform assurance procedures responsive to those risks, and obtain assurance evidence that is sufficient and appropriate to provide a basis for our assurance opinion.
- Obtain an understanding of internal control relevant to the assurance on the ESEF documents in order to design assurance procedures that are appropriate in the circumstances, but not for the purpose of expressing an assurance opinion on the effectiveness of these controls.

- Evaluate the technical validity of the ESEF documents, i.e., whether the file containing the ESEF documents meets the requirements of Commission Delegated Regulation (EU) 2019/815, in the version in force at the date of the financial statements, on the technical specification for this file.
- Evaluate whether the ESEF documents enable an XHTML rendering with content equivalent to the audited annual financial statements and to the audited management report.

FURTHER INFORMATION PURSUANT TO ART. 10 OF THE EU AUDIT REGULATION

We were elected as auditor by the Annual General Meeting on March 14, 2024. We were engaged by the Supervisory Board on June 24, 2024. We have been the auditor of SCHOTT Pharma AG & Co. KGaA without interruption since the abbreviated fiscal year from March 22, 2022 to September 30, 2022.

We declare that the opinions expressed in this auditor's report are consistent with the additional report to the audit committee pursuant to Art. 11 of the EU Audit Regulation (long-form audit report).

In addition to the financial statement audit, we have provided to the Company or entities controlled by it the following services that are not disclosed in the annual financial statements or in the combined management report:

- Review of the condensed interim consolidated financial statements as of March 31, 2024
- Audit of the content of the remuneration report in accordance with Sec. 162 (3) AktG
- Separate limited assurance engagement on the non-financial statement

OTHER MATTER – USE OF THE AUDITOR'S REPORT

Our auditor's report must always be read together with the audited annual financial statements and the audited combined management report as well as the assured ESEF documents. The annual financial statements and the combined management report converted to the ESEF format – including the versions to be published in the Unternehmensregister [German Company Register] – are merely electronic renderings of the audited annual financial statements and the audited combined management report and do not take their place. In particular, the ESEF report and our assurance opinion contained therein are to be used solely together with the assured ESEF documents made available in electronic form.

GERMAN PUBLIC AUDITOR RESPONSIBLE FOR THE ENGAGEMENT

The German Public Auditor responsible for the engagement is Christian Baur.

Eschborn/Frankfurt am Main, December 10, 2024

EY GmbH & Co. KG
Wirtschaftsprüfungsgesellschaft

Baur	Behr
Wirtschaftsprüfer	Wirtschaftsprüferin
[German Public Auditor]	[German Public Auditor]

IMPRINT

DISCLAIMER/FORWARD-LOOKING STATEMENTS

These Annual Financial Statements contain numerous forward-looking statements which are based on the company's assumptions, expectations and intentions. Such statements are indicated by words like "expect", "assume", "intend" or similar wording and are based both on the information currently available to management and on the prevailing environment. These may change at any time. The company accepts no liability for the ultimate correctness and accuracy of any expectations or assumptions expressed in this report. The company also undertakes no obligation to update any of its forward-looking statements to bring them in line with actual developments after these Annual Financial Statements have been published.

PUBLICATION

These Annual Financial Statements were published on 12 December 2024. The document is also available in German. In the event of any discrepancies, the German version shall be authoritative and prevail over the English translation.

In the interest of sustainability, the company's annual reports, interim reports and annual financial statements are not available in printed form. We provide all reports online, as well as for download in PDF format.

ROUNDING, LANGUAGE AND FORMATTING

Due to rounding, individual figures in this document and in other documents may not correspond exactly to the totals stated and percentages shown may not exactly reflect the absolute values to which they relate.

It is also possible that, for technical reasons, the formatting of the accounting records contained in this document deviates from that of records published in accordance with statutory provisions.

CREDITS

Website: www.schott-pharma.com
Investor Relations: www.schott-pharma.com/investor-relations/
Media: www.schott-pharma.com/en/news-and-media
Translation: Ralf Lemster Financial Translations GmbH, Frankfurt am Main
Photography: SCHOTT AG

PUBLISHER

SCHOTT Pharma AG & Co. KGaA
Hattenbergstrasse 10
55122 Mainz, Germany